Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?

güven, hayat; Panpallı Ateş, Mehlika; Çomoğlu, Selim Selçuk; Ferik, Sevgi

doi:10.4274/BMB.galenos.2021.05.066

Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?

Mehlika PANPALLI ATEŞ, (Türkiye Sağlık Bilimleri Üniversitesi, Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Nuroloji Kliniği, Ankara, Türkiye)

Sevgi FERİK, (Kahramanmaraş Necip Fazıl Şehir Hastanesi, Nörofizyoloji Kliniği, Kahramanmaraş, Türkiye)

Hayat GÜVEN, (Türkiye Sağlık Bilimleri Üniversitesi, Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Nuroloji Kliniği, Ankara, Türkiye)

Selim Selçuk ÇOMOĞLU (Türkiye Sağlık Bilimleri Üniversitesi, Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Nuroloji Kliniği, Ankara, Türkiye)

Bağcılar Tıp Bülteni

3 0

Yıl: 2021 Cilt: 6 Sayı: 3 Sayfa Aralığı: 320 - 325 Metin Dili: İngilizce DOI: 10.4274/BMB.galenos.2021.05.066 İndeks Tarihi: 16-01-2022

Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?

Öz:

Objective: In diabetes mellitus (DM) patients, in the development of neuropathy and pain, uric acid (UA), C-reactive protein (CRP), γ-glutamyltransferase (GGT), erythrocyte sedimentation rate (ESR), and fibrinogen increased levels may affect the being of neuropathy by increasing oxidative stress through mechanisms related to inflammation and vascular impairment. In the study, we intended to compare serum UA, GGT, CRP, ESR, and fibrinogen levels in type 2 DM patients, with and without polyneuropathy. Method: Ninety-six type 2 DM patients and 24 participants were included in the study. Physical examinations, neuropathic pain scales, laboratory tests (UA, GGT, CRP, ESR, and fibrinogen levels), and electroneuromyography were evaluated. Results: Ninety-six type 2 DM patients and 24 healthy persons were included in the study as the study and control groups. Diabetic polyneuropathy (DPN) patients with neuropathic pain showed that CRP and low-density lipoprotein cholesterol levels were statistically significantly higher. No statistically significant difference was found between the groups in terms of UA, GGT, CRP, and fibrinogen levels. Conclusion: Increased CRP levels in DPN patients with neuropathic pain may reflect the inflammatory mechanisms involved in the pathogenesis of pain associated with DPN.

Anahtar Kelime:

Diyabetik Polinöropati ve Nöropatik Ağrıda Hangi Belirteçler Rol Oynuyor?

Öz:

Amaç: Diabetes mellitus (DM) hastalarında nöropati ve ağrı gelişiminde ürik asit (UA), C-reaktif protein (CRP), γ-glutamiltransferaz (GGT), eritrosit sedimantasyon hızı (ESR) ve fibrinojen seviyelerinin artışı, enflamasyon ve vasküler hasara bağlı mekanizmalar yoluyla oksidatif stresi artırarak nöropati gelişiminde rol oynayabilir. Bu çalışmada polinöropati olan ve olmayan tip 2 DM’li hastalarda serum UA, GGT, CRP, ESR ve fibrinojen düzeylerini karşılaştırmayı amaçladık. Yöntem: Çalışmaya toplam 96 tip 2 DM hastası ve 24 kişi (kontrol grubu) dahil edildi. Fizik muayeneler, nöropatik ağrı ölçekleri, laboratuvar testleri (UA, GGT, CRP, ESR ve fibrinojen seviyeleri) ve elektronöromiyografi değerlendirildi. Bulgular: Doksan altı tip 2 DM hastası ve 24 sağlıklı kişi çalışma ve kontrol grubu olarak çalışmaya alındı. Nöropatik ağrısı olan diyabetik polinöropati (DPN) hastalarında CRP ve düşük yoğunluklu lipoprotein-kolesterol düzeylerinin istatistiksel olarak anlamlı derecede yüksek olduğu görüldü. Gruplar arasında UA, GGT, CRP ve fibrinojen düzeyleri açısından istatistiksel olarak anlamlı fark bulunmadı. Sonuç: Nöropatik ağrılı DPN hastalarında artmış CRP seviyeleri, DPN ile ilişkili ağrı patogenezinde yer alan enflamatuvar mekanizmaları yansıtabilir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2012;28(Suppl 1):8-14.
2. Stevens MJ, Feldman EL, Greene DA. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabet Med 1995;12(7):566-579.
3. Malik RA, Tesfaye S, Newrick PG, Walker D, Rajbhandari SM, Siddique I, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia 2005;48(3):578- 585.
4. Wannamethee G, Ebrahim S, Shaper AG. Gammaglutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995;142(7):699-708.
5. Backes JM, Howard PA, Moriarty PM. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother 2004;38(1):110-118.
6. Demir M, Bulunmaz M, Müderrisoğlu C, Kose S, Erdem S, Polat H. Role of uric acid in determining cardiovascular risk. İstanbul Med J 2014;15:203-208.
7. Habib SS, A Al Masri A. Relationship of high sensitivity C-reactive protein with presence and severity of coronary artery disease. Pak J Med Sci 2013;29(6):1425-1429.
8. Ates U, Bahadir K, Ergun E, Gollu G, Durmaz M, Gunay F, et al. Determination of Pentraxin 3 levels in diagnosis of Appendicitis in children. Pediatr Int 2020;62(5):624-628.
9. Cengiz AB, Gümüşlü BC, Kayabaşı S, Tansuker HD, Öğreden Ş, Oktay MF. C-reactive protein to albumin ratio as a prognostic predictor in larynx cancer. Bagcilar Med Bull 2020;5(4):179-184.
10. Özyüncü N, Güleç HS, Özcan ÖU, Göksülük H, Gerede Uludağ DM, Erol Ç. Comparison of the Effects of Bare Metal Stents and Drug Eluting Stents on C-Reactive Protein Levels. J Ankara Univ Fac Med 2020;73(3):208-215.
11. Cook NS, Ubben D. Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharmacol Sci 1990;11(11):444-451.
12. Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, et al; Toronto Expert Panel on Diabetic Neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev 2011;27(7):620-628.
13. Ferik S, Güven H, Ateş MP, Conkbayır I, Çomoğlu S, Güven B. Diabetic polyneuropathy, deep white matter lesions, and carotid atherosclerosis: is there any association? Neurol Sci 2018;39(1):103- 110.
14. Yu S, Chen Y, Hou X, Xu D, Che K, Li C, et al. Serum uric acid levels and diabetic peripheral neuropathy in type 2 diabetes: a systematic review and meta-analysis. Mol Neurobiol 2016;53(2):1045-1051.
15. Pafili K, Katsiki N, Mikhailidis DP, Papanas N. Serum uric acid as a predictor of vascular complications in diabetes: an additional case for neuropathy. Acta Diabetol 2014;51(5):893-894.
16. Kiani J, Habibi Z, Tajziehchi A, Moghimbeigi A, Dehghan A, Azizkhani H. Association between serum uric acid level and diabetic peripheral neuropathy (A case-control study) Caspian J Intern Med 2014;5(1):17-21.
17. Papanas N, Katsiki N, Papatheodorou K, Demetriou M, Papazoglou D, Gioka T, et al. Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus. Angiology 2011;6(4):291-295.
18. Uher T, Bob P. Neuropathic pain, depressive symptoms, and C-reactive protein in sciatica patients. Int J Neurosci 2013;123(3):204-208.
19. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet 2009;373(9670):1175-1182.
20. Ge S, Xie J, Zheng L, Yang L, Zhu H, Cheng X, et al. Associations of serum anti-ganglioside antibodies and inflammatory markers in diabetic peripheral neuropathy. Diabetes Res Clin Pract 2016;115:68-75.
21. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009;58(7):1634-1640.
22. Ridker PM, Libby P. Risk factors for atherothrombotic disease. In: Bonow RO, Mann DL, Zipes DP, Libby P (editors). Braunwald’s Heart Disease. Saunders Philadelphia: Elsevier, 2014;39:1003-1026.
23. Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab 2009;94(6):2157-2163.

APA	Panpallı Ateş M, Ferik S, güven h, Çomoğlu S (2021). Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?. , 320 - 325. 10.4274/BMB.galenos.2021.05.066
Chicago	Panpallı Ateş Mehlika,Ferik Sevgi,güven hayat,Çomoğlu Selim Selçuk Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?. (2021): 320 - 325. 10.4274/BMB.galenos.2021.05.066
MLA	Panpallı Ateş Mehlika,Ferik Sevgi,güven hayat,Çomoğlu Selim Selçuk Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?. , 2021, ss.320 - 325. 10.4274/BMB.galenos.2021.05.066
AMA	Panpallı Ateş M,Ferik S,güven h,Çomoğlu S Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?. . 2021; 320 - 325. 10.4274/BMB.galenos.2021.05.066
Vancouver	Panpallı Ateş M,Ferik S,güven h,Çomoğlu S Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?. . 2021; 320 - 325. 10.4274/BMB.galenos.2021.05.066
IEEE	Panpallı Ateş M,Ferik S,güven h,Çomoğlu S "Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?." , ss.320 - 325, 2021. 10.4274/BMB.galenos.2021.05.066
ISNAD	Panpallı Ateş, Mehlika vd. "Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?". (2021), 320-325. https://doi.org/10.4274/BMB.galenos.2021.05.066

APA	Panpallı Ateş M, Ferik S, güven h, Çomoğlu S (2021). Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?. Bağcılar Tıp Bülteni, 6(3), 320 - 325. 10.4274/BMB.galenos.2021.05.066
Chicago	Panpallı Ateş Mehlika,Ferik Sevgi,güven hayat,Çomoğlu Selim Selçuk Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?. Bağcılar Tıp Bülteni 6, no.3 (2021): 320 - 325. 10.4274/BMB.galenos.2021.05.066
MLA	Panpallı Ateş Mehlika,Ferik Sevgi,güven hayat,Çomoğlu Selim Selçuk Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?. Bağcılar Tıp Bülteni, vol.6, no.3, 2021, ss.320 - 325. 10.4274/BMB.galenos.2021.05.066
AMA	Panpallı Ateş M,Ferik S,güven h,Çomoğlu S Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?. Bağcılar Tıp Bülteni. 2021; 6(3): 320 - 325. 10.4274/BMB.galenos.2021.05.066
Vancouver	Panpallı Ateş M,Ferik S,güven h,Çomoğlu S Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?. Bağcılar Tıp Bülteni. 2021; 6(3): 320 - 325. 10.4274/BMB.galenos.2021.05.066
IEEE	Panpallı Ateş M,Ferik S,güven h,Çomoğlu S "Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?." Bağcılar Tıp Bülteni, 6, ss.320 - 325, 2021. 10.4274/BMB.galenos.2021.05.066
ISNAD	Panpallı Ateş, Mehlika vd. "Which Markers Play a Role in Diabetic Polyneuropathy and Neuropathic Pain?". Bağcılar Tıp Bülteni 6/3 (2021), 320-325. https://doi.org/10.4274/BMB.galenos.2021.05.066